IGM Biosciences, Inc. IGMS
1.27 0.00 (+0.00%)
At closeAug 14, 2025, 4:00 PM EDT
1.27 Day range 1.27
6.15 52-week range 22.50
- YTD
- -79.21%
- 1 year
- -85.70%
Analyst view
Consensus: buy
Buy
Price target (mean) 19.73 +1453.3% upside
Now 1.27
- Target (low)
- 9.00
- Target (mean)
- 19.73
- Target (high)
- 48.00
Ratings (0m) 11 6 buy · 4 hold · 1 sell
- Strong buy2
- Buy4
- Hold4
- Sell0
- Strong sell1
Recommendation trend
- This month 11
- 1 month ago 10
- 2 months ago 10
- 3 months ago 10
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -0.785 | -0.93 – -0.69 | -1.01 | +22.3% | 270.00K | -58.5% | 6 |
| Next quarter | -0.6575 | -0.85 – -0.45 | -0.83 | +20.8% | 2.48M | +399.7% | 4 |
| Current year | -3.38 | -3.62 – -3.25 | -4.71 | +28.3% | 2.58M | +21.1% | 6 |
| Next year | -2.32 | -3.56 – -1.45 | -3.38 | +31.4% | 7.26M | +181.6% | 6 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 6, 2024 | BMO Capital | Initiated | — | Outperform |
| Nov 11, 2024 | Stifel | Maintained | Buy | Buy |
| Oct 18, 2024 | RBC Capital | Maintained | Outperform | Outperform |
| Oct 1, 2024 | Guggenheim | Maintained | Buy | Buy |
| Oct 1, 2024 | Wedbush | Maintained | Outperform | Outperform |
| Oct 1, 2024 | RBC Capital | Maintained | Outperform | Outperform |
| Oct 1, 2024 | JP Morgan | Downgrade | Neutral | Underweight |
| Oct 1, 2024 | Truist Securities | Downgrade | Buy | Hold |
| Sep 5, 2024 | HC Wainwright & Co. | Maintained | Neutral | Neutral |
| Aug 23, 2024 | Truist Securities | Maintained | Buy | Buy |
| Aug 15, 2024 | Wedbush | Maintained | Outperform | Outperform |
| Aug 15, 2024 | RBC Capital | Reiterated | Outperform | Outperform |
| Aug 15, 2024 | JP Morgan | Maintained | Neutral | Neutral |
| May 24, 2024 | HC Wainwright & Co. | Reiterated | Neutral | Neutral |
| May 9, 2024 | Wedbush | Reiterated | Outperform | Outperform |
| Apr 18, 2024 | HC Wainwright & Co. | Reiterated | Neutral | Neutral |
| Mar 12, 2024 | HC Wainwright & Co. | Maintained | Neutral | Neutral |
| Mar 8, 2024 | RBC Capital | Reiterated | Outperform | Outperform |
| Mar 8, 2024 | Wedbush | Reiterated | Outperform | Outperform |
| Feb 9, 2024 | RBC Capital | Upgrade | Sector Perform | Outperform |
| Dec 15, 2023 | B of A Securities | Downgrade | Buy | Neutral |
| Dec 7, 2023 | HC Wainwright & Co. | Downgrade | Buy | Neutral |
| Dec 6, 2023 | RBC Capital | Maintained | Sector Perform | Sector Perform |
| Nov 15, 2023 | Morgan Stanley | Maintained | Equal-Weight | Equal-Weight |
| Nov 15, 2023 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Nov 14, 2023 | Stifel | Maintained | Buy | Buy |
| Nov 14, 2023 | RBC Capital | Maintained | Sector Perform | Sector Perform |
| Sep 6, 2023 | Truist Securities | Reiterated | Buy | Buy |
| Aug 17, 2023 | RBC Capital | Reiterated | Sector Perform | Sector Perform |
| Aug 7, 2023 | Needham | Downgrade | Buy | Hold |
